Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation
Last Updated: Thursday, May 4, 2023
Data from a large international multicenter cohort trial demonstrated that patients with myelofibrosis with multi-hit TP53 mutations, versus single-hit or wild-type, are at increased risk for relapse (multi-hit 52%, single-hit 17%, wild-type 21%) and shorter 6-year overall survival (25%, 56%, and 64%, respectively).
Advertisement
News & Literature Highlights
